CN117736141A - 用于治疗肾脏疾患的化合物 - Google Patents
用于治疗肾脏疾患的化合物 Download PDFInfo
- Publication number
- CN117736141A CN117736141A CN202311697211.0A CN202311697211A CN117736141A CN 117736141 A CN117736141 A CN 117736141A CN 202311697211 A CN202311697211 A CN 202311697211A CN 117736141 A CN117736141 A CN 117736141A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- use according
- halogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185871.3 | 2018-07-26 | ||
| EP18185871 | 2018-07-26 | ||
| PCT/EP2019/070251 WO2020021097A1 (en) | 2018-07-26 | 2019-07-26 | Compounds for use in treating kidney disorders |
| CN201980048869.4A CN112469442B (zh) | 2018-07-26 | 2019-07-26 | 用于治疗肾脏疾患的化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980048869.4A Division CN112469442B (zh) | 2018-07-26 | 2019-07-26 | 用于治疗肾脏疾患的化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117736141A true CN117736141A (zh) | 2024-03-22 |
Family
ID=63077813
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311697211.0A Pending CN117736141A (zh) | 2018-07-26 | 2019-07-26 | 用于治疗肾脏疾患的化合物 |
| CN201980048869.4A Active CN112469442B (zh) | 2018-07-26 | 2019-07-26 | 用于治疗肾脏疾患的化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980048869.4A Active CN112469442B (zh) | 2018-07-26 | 2019-07-26 | 用于治疗肾脏疾患的化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200085810A1 (https=) |
| EP (2) | EP3826679B1 (https=) |
| JP (2) | JP7478133B2 (https=) |
| KR (1) | KR102860768B1 (https=) |
| CN (2) | CN117736141A (https=) |
| AU (1) | AU2019310919B2 (https=) |
| CA (1) | CA3104793A1 (https=) |
| ES (1) | ES3005632T3 (https=) |
| IL (1) | IL280368B2 (https=) |
| MX (1) | MX2021000976A (https=) |
| PL (1) | PL3826679T3 (https=) |
| TW (1) | TWI891608B (https=) |
| WO (1) | WO2020021097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| WO2022006277A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Methods for treatment of fibrotic kidney diseases |
| US11814354B2 (en) * | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
| US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
| ES2314633T3 (es) | 2004-03-26 | 2009-03-16 | F. Hoffmann-La Roche Ag | Tetrahidrocarbazoles y derivados. |
| DE602005015962D1 (de) | 2004-05-03 | 2009-09-24 | Hoffmann La Roche | Indolylderivate als liver-x-rezeptormodulatoren |
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| AR079022A1 (es) * | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| WO2013037703A1 (en) | 2011-09-12 | 2013-03-21 | F. Hoffmann-La Roche Ag | 3 -pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents |
| WO2014180741A1 (en) | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| CA2917277A1 (en) | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Losmapimod for use in treating glomerular disease |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
-
2019
- 2019-07-25 US US16/522,116 patent/US20200085810A1/en not_active Abandoned
- 2019-07-26 AU AU2019310919A patent/AU2019310919B2/en active Active
- 2019-07-26 TW TW108126640A patent/TWI891608B/zh active
- 2019-07-26 EP EP19749657.3A patent/EP3826679B1/en active Active
- 2019-07-26 IL IL280368A patent/IL280368B2/en unknown
- 2019-07-26 KR KR1020217002388A patent/KR102860768B1/ko active Active
- 2019-07-26 CN CN202311697211.0A patent/CN117736141A/zh active Pending
- 2019-07-26 WO PCT/EP2019/070251 patent/WO2020021097A1/en not_active Ceased
- 2019-07-26 PL PL19749657.3T patent/PL3826679T3/pl unknown
- 2019-07-26 ES ES19749657T patent/ES3005632T3/es active Active
- 2019-07-26 CA CA3104793A patent/CA3104793A1/en active Pending
- 2019-07-26 JP JP2021504186A patent/JP7478133B2/ja active Active
- 2019-07-26 CN CN201980048869.4A patent/CN112469442B/zh active Active
- 2019-07-26 MX MX2021000976A patent/MX2021000976A/es unknown
- 2019-07-26 EP EP24213767.7A patent/EP4537901A3/en active Pending
-
2021
- 2021-03-19 US US17/206,955 patent/US20210275514A1/en not_active Abandoned
-
2024
- 2024-03-27 US US18/618,124 patent/US20240325372A1/en active Pending
- 2024-04-19 JP JP2024068208A patent/JP2024096989A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112469442B (zh) | 2024-04-09 |
| EP4537901A2 (en) | 2025-04-16 |
| KR20210038884A (ko) | 2021-04-08 |
| CN112469442A (zh) | 2021-03-09 |
| AU2019310919A1 (en) | 2021-01-07 |
| PL3826679T3 (pl) | 2025-03-10 |
| EP3826679C0 (en) | 2024-11-27 |
| IL280368B2 (en) | 2024-02-01 |
| US20240325372A1 (en) | 2024-10-03 |
| JP2024096989A (ja) | 2024-07-17 |
| ES3005632T3 (en) | 2025-03-14 |
| EP4537901A3 (en) | 2025-05-21 |
| JP7478133B2 (ja) | 2024-05-02 |
| US20210275514A1 (en) | 2021-09-09 |
| EP3826679A1 (en) | 2021-06-02 |
| EP3826679B1 (en) | 2024-11-27 |
| TW202019486A (zh) | 2020-06-01 |
| US20200085810A1 (en) | 2020-03-19 |
| AU2019310919B2 (en) | 2025-04-03 |
| CA3104793A1 (en) | 2020-01-30 |
| WO2020021097A1 (en) | 2020-01-30 |
| JP2021531308A (ja) | 2021-11-18 |
| TWI891608B (zh) | 2025-08-01 |
| IL280368B1 (en) | 2023-10-01 |
| IL280368A (en) | 2021-03-25 |
| MX2021000976A (es) | 2021-03-31 |
| KR102860768B1 (ko) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325372A1 (en) | Compounds for use in treating kidney disorders | |
| Ninou et al. | Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis | |
| RS54492B1 (sr) | Kinazni inhibitor koji reguliše signalni put apoptoze | |
| EP2651403B1 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| WO2011058766A1 (en) | Aryl carboxamide derivatives as ttx-s blockers | |
| US20220280484A1 (en) | Novel use | |
| KR20200015888A (ko) | Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체 | |
| WO2012020567A1 (en) | Acyl piperazine derivatives as ttx-s blockers | |
| WO2019173482A1 (en) | 4-aminoquinoline compounds for the treatment of angiogenesis | |
| Shi et al. | Losartan attenuates scar formation in filtering bleb after trabeculectomy | |
| US20240279201A1 (en) | Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease | |
| CA3168728A1 (en) | Compositions and methods for treating renal injury | |
| EP4705296A1 (en) | Heteroarylindole inhibitors of apol-1 | |
| KR20080064911A (ko) | 선택적 노르아드레날린 재흡수 억제제와 ｐｄｅｖ 억제제의조합물 | |
| US9403755B2 (en) | Isometheptene isomer | |
| CN112384497A (zh) | 具有选择性nox抑制活性的新型磺酰胺衍生物 | |
| HK40040900A (en) | Compounds for use in treating kidney disorders | |
| HK40102350A (zh) | 用於治疗肾脏疾患的化合物 | |
| HK40040900B (zh) | 用於治疗肾脏疾患的化合物 | |
| Kalogeropoulou | Investigation of (bio) isosterism in anti-fibrotic “leads” |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40102350 Country of ref document: HK |